Jacopo Andreose

Jacopo Andreose is an executive with 30 years of international experience in the pharmaceutical and biotechnology industry, with a proven ability to lead international teams, drive change, and strengthen capabilities within complex, multifunctional organizations.

He previously served as Chief Executive Officer of Angelini Pharma from 2022 to 2025. Since May 2025, he has been a member of the Executive Board of GRIN Therapeutics, and since June 2025, a member of the Board of Directors of Angelini Holding S.p.A.

Over the course of his career, he has held roles of increasing responsibility at several leading global pharmaceutical companies, including Gilead Sciences, GlaxoSmithKline/ViiV Healthcare, Bristol-Myers Squibb, and Abbott. He has successfully led the launch and commercialization of innovative medicines in high-impact therapeutic areas such as immunology, oncology, virology, and neurosciences.

His scientific and managerial education includes a PhD in Pharmacology and a Master’s degree in Pharmacy from the University of Milan, a Master’s degree in Management from the BI Norwegian School of Management in Oslo, and a postdoctoral fellowship in cellular and molecular physiology at the Yale University School of Medicine in the United States.

He has lived and worked in the United States, the United Kingdom, Italy, Scandinavia, France, and Switzerland, and has extensive experience in the markets of Japan, China, and Latin America.